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The intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes (PMN)
were evaluated. Gemifloxacin reached intracellular concentrations eight times higher than extracellular con-
centrations. The uptake was rapid, reversible, and nonsaturable and was affected by environmental temper-
ature, cell viability, and membrane stimuli. At therapeutic extracellular concentrations, gemifloxacin showed
intracellular activity against Staphylococcus aureus.
Most fluoroquinolones are able to concentrate intracellu-
larly in human phagocytic cells and remain active against
facultatively and obligately intracellular pathogens, such as
mycobacteria, Legionella spp., Streptococcus pneumoniae, and
Staphylococcus aureus (16). Gemifloxacin is a new fluoroquin-
olone which displays more potent activity than sparfloxacin
against gram-positive organisms and anaerobes (5, 7, 10). In
addition, it shows excellent in vitro activity against other respi-
ratory pathogens, such as Chlamydia pneumoniae, Haemophi-
lus influenzae, and Mycoplasma pneumoniae (1, 19). The pur-
pose of this study was to evaluate the uptake of gemifloxacin by
human polymorphonuclear leukocytes (PMN). Also evaluated
were the mechanisms involved in the penetration of this agent
into the PMN and its intracellular activity against S. aureus.
PMN uptake of radiolabeled gemifloxacin (64.5 mCi/mg; SB
Pharmaceuticals, Harlow, United Kingdom) was determined
by means of a velocity gradient centrifugation technique de-
scribed by Klempner and Styrt (6). PMN were incubated in
Hanks balanced salt solution containing different concentra-
tions of gemifloxacin (0.1 to 25 mg/ml). After different incuba-
tion periods at 37°C (1 to 60 min), cells were separated from
the extracellular solution by centrifugation through a water-
impermeable silicone oil barrier. A 10-ml aliquot of the extra-
cellular medium and the entire cell pellet were placed in 3 ml
of scintillation fluid (Ready Micro; Beckman Instruments, Inc.,
Fullerton, Calif.) and counted in a liquid scintillation counter
(model LS 1801; Beckman). The accumulation rate of gemi-
floxacin was calculated and expressed as a cellular-to-extracel-
lular-concentration ratio (C/E ratio) (11). The efflux of cell-
associated gemifloxacin was also studied. All assays were
performed in duplicate with PMN from four different donors.
Data were expressed as means 6 standard deviations. Differ-
ences among groups were compared by variance analysis, used
to assess statistical significance at a P value of #0.05.
The kinetics of the uptake and efflux of gemifloxacin by
PMN are shown in Fig. 1. The uptake of gemifloxacin by the
PMN was rapid and high. At extracellular concentrations of 2
mg/ml, the C/E ratios were higher than 7 after 20 min of
incubation. This value is similar to those described for cipro-
floxacin, ofloxacin, levofloxacin, and sparfloxacin (2, 13, 14)
and slightly lower than those described for trovafloxacin and
moxifloxacin (17, 18). Reversibility of binding was rapid for
gemifloxacin, with 60% of the cell-associated drug being lost
after 5 min. The effect of extracellular concentrations of gemi-
floxacin on PMN uptake is presented in Fig. 2. Cell-associated
gemifloxacin was not saturable at concentrations ranging from
0.1 to 25 mg/ml.
Further studies were performed to elucidate the mechanism
of gemifloxacin uptake by PMN (2, 12). The influences of
environmental temperature (4 versus 37°C), cell viability, pH
(pH 5 to 8), metabolic inhibitors (sodium fluoride at 1.5 3
1023 M, sodium cyanide at 1.5 3 1023 M, carbonyl cyanide
m-chlorophenylhydrazone at 1.5 3 1025 M, and 2,4-dinitro-
phenol at 1 3 1024 M; Sigma Chemical Co., St. Louis, Mo.),
potential competitive substrates (adenosine at 1 mM, D-glu-
cose at 1 mM, and lysine at 1 mM; Sigma), and stimuli of PMN
membranes (phorbol myristate acetate [PMA] at 200 nM [Sig-
ma] and either opsonized zymosan [0.9 mg/liter; Sigma] or S.
aureus ATCC 25923) were evaluated. The intracellular pene-
tration of gemifloxacin was significantly impaired at 4°C (C/E
ratio, 1.0 6 0.3 versus 8.8 6 2.3) and significantly increased
when dead PMN were used (26.8 6 7.9 versus 8.8 6 2.3). This
remarkable increase has not been shown by any other fluoro-
quinolone in formalin-killed PMN. A possible explanation
might be that formalin causes structural changes in the PMN
which favor nonspecific binding of the gemifloxacin. Gemi-
floxacin uptake by the PMN was not significantly affected by
external pH. Neither the metabolic inhibitors nor the potential
competitive substrates (data not shown) affected the intracel-
lular penetration of this quinolone. The penetration of gemi-
floxacin was unaffected by phagocytosis of opsonized zymosan
or by S. aureus. PMA stimulation of PMN membranes signif-
icantly increased the uptake of this fluoroquinolone by human
PMN (C/E ratio, 58.1 6 15.9). This controversial effect could
be related to the fact that the activation of PMN by opsonized
particles differed from that by PMA (8).
The mechanism involved in the intraphagocytic penetration
of gemifloxacin is not yet known, and no single model can be
postulated in view of our results. Although most data point to
a passive mechanism, as has been postulated for many fluoro-
quinolones, others are typical of an active mechanism. In fact,
a passive mechanism (2, 17), a carrier-mediated process (9),
and an energy mechanism have been postulated for different
fluoroquinolones (3, 12, 18, 20).
To evaluate the intracellular activities of antimicrobial
agents, a previously described method was used (11). The
MICs and minimal bactericidal concentrations (MBCs) of cip-
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rofloxacin (Bayer AG, Leverkusen, Germany), trovafloxacin
(Pfizer Central Research, Groton, Conn.), and gemifloxacin
against S. aureus ATCC 25923 were 0.25, 0.03, and 0.015 mg/
ml, respectively. The data were expressed as percentages of
surviving staphylococci compared with control levels (without
antimicrobial agents) at 3 h. In addition to determining bacte-
rial survival, morphologic studies were also routinely per-
formed at time zero and after 3 h of incubation in order to
evaluate the disposition of bacteria (cell associated or extra-
cellular). All assays were performed in duplicate with PMN
from four different donors. Data were expressed as means 6
standard deviations. Differences among groups were compared
by variance analysis, used to assess statistical significance at a
P value of #0.05. At therapeutic concentrations (0.5, 1, and 5
mg/ml), gemifloxacin showed significant intracellular activity
against S. aureus, similar to that observed for ciprofloxacin and
lower than that observed for trovafloxacin (Fig. 3). Based on
intrinsic activity and C/E values, greater intracellular activity
would be expected for gemifloxacin compared to ciprofloxacin.
This discrepancy might be related to different degrees of flu-
oroquinolone activity in the intracellular compartment or to
limitations in the method of detecting differences in activity
among compounds with very high intracellular activities (4).
In summary, gemifloxacin penetrates into human PMN,
reaching high intracellular concentrations and remaining ac-
tive intracellularly. The high antimicrobial activity of this agent
against potential intracellular pathogens enhances its useful-
ness in clinical settings.
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FIG. 1. Gemifloxacin uptake by human PMN and efflux of PMN-associated
gemifloxacin after the removal of the extracellular drug (n 5 4). The extracellular
concentration was 2 mg/ml. Error bars indicate standard deviations.
FIG. 2. Gemifloxacin uptake by human PMN at different extracellular con-
centrations (n 5 4). Incubations were carried out for 20 min. Error bars indicate
standard deviations.
FIG. 3. Intracellular activities of gemifloxacin, ciprofloxacin, and trovafloxa-
cin against S. aureus in human PMN in a 3-h assay (n 5 4). Data are expressed
as percentages of intracellular surviving staphylococci compared to the level of
intracellular surviving staphylococci in controls without antimicrobial agents
(taken as 100%). Asterisks, P # 0.05 compared with controls.
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